Enfortumab plus pembrolizumab for muscle-invasive bladder cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests how well two anti-cancer medicines—enfortumab vedotin and pembrolizumab—work for people with muscle-invasive bladder cancer that has spread to nearby lymph nodes (but not distant organs). It may help shrink the cancer and improve treatment outcomes before or around planning major surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have confirmed muscle-invasive urothelial (bladder/urinary tract) cancer.
- Your cancer stage fits specific categories (T2–T4 and/or N1–N3 with no distant spread; or T1 with N2–N3 with no distant spread).
- Your lymph nodes must look positive on scans and meet the study’s imaging size rules, and biopsy confirmation is preferred (but sometimes not required).
- You have not had prior treatment for muscle-invasive or metastatic urothelial bladder cancer.
- Your body must be strong enough for treatment (ECOG 0–1, and kidney, liver, blood counts, and clotting tests meet required minimums).
- You must be able to use effective birth control (if applicable) and not donate sperm for a set period after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, given before surgery for upper tract urothelial cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes for patients who are candidates for surgery.
This trial tests a new drug, PF-08634404, either by itself or together with another drug called enfortumab vedotin, for people with advanced bladder cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to treat bladder cancer that has grown into the muscle of the bladder. The goal is to shrink or eliminate the cancer so that surgery to remove the bladder may not be needed.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to treat muscle-invasive bladder cancer. The goal is to see if this can help patients avoid having their bladder removed. It is for people who cannot or choose not to have surgery.
This study tests two drugs, enfortumab vedotin and pembrolizumab, to see if they can help people with muscle-invasive bladder cancer avoid removing their bladder. The drugs are given before the standard surgery to possibly shrink the tumor and improve outcomes.
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.